The invention in this application generally is the CGRP receptor antagonist, the new chemical compound of formula I and it regards the salt which that medicine it can allow. In addition as for the invention in this application, one headache and other headache, nervous Characteristic vasodilatation, the nervous Characteristic inflammation, the heat damage and the wraparound Characteristic shock, blush, the breathing apparatus inflammatory disease (for example, asthma), and the chronic blockade Characteristic lung disease (COPD) which relate to the change of life fault were included, in dealing with the CGRP-related fault, it regards also the medicine constituent and the manner which use the said chemical compound.本願発明は概して、CGRP受容体アンタゴニストである、式Iの新規な化合物およびその医薬的に許容し得る塩に関する。本願発明はまた、片頭痛および他の頭痛、神経性血管拡張、神経性炎症、熱損傷、循環性ショック、更年期障害に関係する紅潮、呼吸器炎症性疾患(例えば、喘息)、および慢性閉塞性肺疾患(COPD)を含めた、CGRP関連障害の処置における、該化合物を使用する医薬組成物および方法にも関する。
